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ABSTRACT
Dyspepsia is a complaint commonly found in daily practice. Functional dyspepsia is considered if the organic 
cause of dyspepsia is not found. The pathophysiology of functional dyspepsia has not been fully understood. 
However there are three main pathophysiology, which are: motility disturbance, non-motility disturbance, and 
psychosocial factor. Several digestive tract hormones are ghrelin, motilin, cholecystokinin (CCK), peptide YY 
(PYY), somatostatin, glucagon-like-peptide 1 (GLP), are thought to play role in the pathophysiology of functional 
dyspepsia, particularly in the regulation of digestive tract motility. Currently, a new paradigm in digestive tract 
disturbance treatment is developing, such as motilin receptor agonist therapy (for example mitemcinal) and 
ghrelin receptor agonist therapy, which is used as one of the new modalities in treatment of dyspepsia.
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ABSTRAK
Dispepsia adalah keluhan yang kerap ditemui dalam praktik sehari-hari. Dikatakan sebagai dispepsia 
fungsional jika penyebab organik tidak ditemukan. Pato siologi dispepsia fungsional belum sepenuhnya 
dimengerti namun terdapat tiga pato siologi utama yakni gangguan motilitas, gangguan non-motilitas dan 
faktor psikososial. Dewasa ini diketahui adanya peran hormon saluran cerna seperti hormon ghrelin, motilin, 
cholecystokinin (CCK), peptida YY (PYY), somatostatin, glucagon-like-peptide 1 (GLP) dalam pato siologi 
dispepsia fungsional khususnya dalam pengaturan motilitas saluran cerna. Pengetahuan akan hormon-hormon 
ini menjadikan adanya paradigma baru dalam terapi gangguan saluran cerna yakni dengan dikembangkannya 
terapi agonis reseptor motilin (misalnya mitemcinal) dan ghrelin (TZP-101) sebagai salah satu modalitas baru 
dalam terapi dispepsia.
Kata kunci: dispepsia, dispepsia fungsional, motilin, ghrelin, cholecystokinin, agonis reseptor motilin, agonis 
reseptor ghrelin
INTRODUCTION
Dyspepsia is explained as sensation of discomfort 
or pain in the upper abdomen area.1,2 This complain 
commonly happen in general population, with the 
average of 25% (ranging from 13-40%) incidence 
annually.1,3 The organic cause of dyspepsia, such as 
duodenal ulcer, is found in only 40% of patients with 
dyspepsia. This means, the rest or about 60% experience 
functional dyspepsia.5,6,7 Functional dyspepsia (FD) is 
a condition which cause and pathophysiology have 
not yet been fully understood.2,3 Several digestive tract 
hormones, such as: ghrelin, motilin, cholecystokinin 
(CCK), Peptide YY (PYY), somatostatin, glucagon-
like-peptide 1 (GLP) are thought to play role in 
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functional dyspepsia, particularly in the regulation 
of digestive tract motility. Therefore, knowledge on 
these hormones may help us in the management of 
functional dyspepsia.
De nition of Functional Dyspepsia
Based on Rome III consensus in year 2005, it is 
agreed that dyspepsia is explained as sensation of pain or 
discomfortness in the mid-upper abdomen, either acute 
or chronic.1 If this dyspepsia complaint is not caused by 
organic abnormality, systemic, or metabolic disease, 
thus it is considered as functional dyspepsia (FD).1-
3,7,13,14 Currently there are two categories of FD, which 
are: dyspepsia complaints which are induced by meal 
or also known as postprandial distress syndrome (PDS) 
and epigastric pain or epigastric pain syndrome (EPS).1,7
PATHOPHYSIOLOGY OF FUNCTIONAL DYSPEPSIA
Several theories about pathophysiology of FD has 
been known, such as: gastric emptying disturbance, 
hypersensitivity towards gastric distention, accomodation 
disturbance of proximal gaster towards food, gastric 
acid hypersection, H. pylori infection, disturbance in 
duodenojejunal motility, duodenal hypersensitivity 
towards acid or particular nutrients, and disturbance 
of central nervous system.1,4,11,16,17 In summary, these 
different pathophysiology is explained in  gure 1 below.
motoric function depending on the location, which 
are: proximal and distal part. Distal part of the gaster 
regulates mixing and grinding gastric contents into 
smaller form, so that it will be easier to distribute 
to duodenum, while the proximal gaster is more act 
as food reservoir.14,17 This food reservoir re ex is 
known as accomodation re ex.21 About 30 to 70% 
FD patients experience disturbance in this re ex. 
Consumed food is directed to the distal part of the 
gaster, thus causing sense of satiety.21,22. Presence 
of digestive tract motoric disturbance, such as 
delayed emptying will cause food distribution 
disturbance in the gaster. Besides, it may also 
cause disturbance in food accomodation process, 
antrum hypomotility, and gastric dysrhythmias and 
duodenum and jejunum motility changes.19,22
2. Visceral hypersensitivity
 Thirty  ve up to 50% of FD patients experience 
hypersensitivity towards gastric distention stimuli. 
FD patients will experience complaints, such as 
postprandial pain and burping as there is addition 
of gastric volume, which in normal condition 
not being complained of.21,23 FD patients also has 
gastric and duodenal hypersensitivity towards acid, 
bile acid, and particular nutrients, such as fat.12,17,19 
Presence of fatty acid in the duodenum through 
the role of cholecystokinin (CCK) hormone will 
stimulate relaxation in the proximal part of gaster 
and increase sensitivity to gastric distention. This 
will  nally cause complaint of nausea.12,14,20
3. Psychosocial factor
 Brain gut-axis (BGA) regulates communication 
between brain and digestive tract system (intestine). 
This BGA comprises of three parts, which are: 
enteric nervous system (ENS), autonomic nervous 
There are three main mechanism in the 
pathophysiology of FD, including: digestive tract 
motility, visceral hypersensitivity, and psychosocial 
factor.5,17,18,19
1. Motility disturbance
 Mostly reported motility disturbances are gastric 
emptying disturbance and gastric accomodation 
re eks disturbance.14,17 Gaster has two different Figure 2. Brain-gut-axis24
Figure 1. Pathophisiologic mechanism in functional dyspepsia
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system (ANS), and central nervous system (CNS). 
ANS distribute information which is received 
from the intestine to the intestine through vagus 
and spinal afferent pathway. Further, after being 
processed in brain level, information is sent back 
to the digestive tract through ANS, particularly 
parasympatic and sympathic efferent (Figure 2).24
HORMONES WHICH INFLUENCE UPPER 
DIGESTIVE TRACT FUNCTION
Several hormones produced by the intestine, 
especially as response to food, influence digestive 
tract sensoric and motoric function, both in fasting and 
postprandial condition.11 Motilin, somatostatin, and 
ghrelin play role in digestive tract motoric activity in 
fasting condition, while cholecystokinin (CCK), gastrin, 
leptin, Peptide YY (PYY), glucagon-like-peptida 1 
(GLP-1), GLP-2, neurotensin, pancreas polypeptide and 
others in uence postprandial activity. GLP-1, PYY, and 
ghrelin, also play role in the regulation of gastric motoric 
function (see Figure 3).8,10,18,19,21-23 
Gastrin
Gastrin in large amountis produced by speci c 
endocrine cell (G cell) in gastric antrum as response 
to the presence of food in small amount which can 
be found in proximal gaster, duodenum, jejunum, 
ileum, and pancreas.8,22,26 These hormones play role 
in the gastric acid secretion.10,11,13,26 Besides, gastrin 
also has effect in stimulating cell growth in gastric 
mucosa and few cancers.26 In FD patients, it is known 
that there is higher level of gastrin compared to 
healthy individuals.8-10 This increase of gastrin level 
is especially found in postprandial compared tofasting 
condition.9
Elevation of gastrin level in FD is assumed as 
impact of autonomic nervous system disturbance and 
role of H. pylori infection.8,9,22,27 Gastrin may also 
not increased signi cantly in FD patients compared 
to healthy individuals.27 This is caused by CCK 
inhibition effect towards production of gastrin due to 
H. pylori infection. Currently, H. pylori eradication is 
recommended as a therapy modality of FD.13,22
Ghrelin
Ghrelin, a hormone which is relatively new to be 
discovered, is produced by oxyntic cell in the gaster. 
This hormone is produced during fasting, together 
with motilin, somatostatin dan xenin. The function 
of this hormone is to increase gastric emptying rate 
and also may increase appetite.8,11,26 Its role in FD 
pathophysiology is still not widely known considering 
that in FD patients, this hormone level during fasting 
might be low, normal, or even increased.8
Secretin
The role of this hormone towards FD pathophysiology 
is not much known. This hormone may cause gastric 
dysrhythmias, particularly hinderance in gastric 
emptying process.8 Secretin is produced by special 
enteroendocrine cell in the small intestine (called as 
S-cell) and has main function in stimulating pancreatic 
 uid and bicarbonate, particularly to neutralize gastric 
acid as it enters duodenum (negative feedback).26
Figure 3. (a) Hormone during fasting and (b) postprandial
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Cholecystokinin
CCK hormone, previously called as pancreozimin, 
is produced by I-cell in small intestine epithelial mucosa 
and is secreted through duodenum as response to the 
presence of food, especially to the presence of fat and 
protein. This hormone regulates postprandial activity.8,11,26 
CCK is a rapid onset hormone and peak level is reached 
in 15-30 minutes after meal and the level return to the 
basal level after 3 to 5 hours.26,27 Similar to gastrin, CCK 
hormone is also controlled by vagus nerve.10 CCK in the 
circulation will bind speci cally to CCK1 receptor. Role 
of CCK includes regulation of gastric acid secretion, bile 
duct contraction, decrease gastric emptying rate, and also 
stimulate sense of satiety.8,26
Somatostatin
This  hormone i s  produced by  spec if ic 
enteroendocrine cells, which are D-cell in the gaster. 
The function of this hormone is to inhibit gastric acid 
secretion, inhibit digestive tract motility, and decrease 
splanchnic blood  ow.26 Somatostatin is thought to 
play role in the regulation of digestive tract motoric 
activity in fasting condition.22 Several writers associate 
the severity degree of dyspepsia complaints with the 
elevation level of gastrin, CCK, and somatostatin.22 In 
FD patients, it is obtained that the somatostatin level 
is higher compared to healthy individuals, though the 
exact cause of this elevation is not known.22
Motilin
Motilin is produced by endocrine cells from 
duodenal epithelial and is released to the blood 
periodically and repeatedly, in accordance with 
migrating motor complex (MMC) activity. Release of 
this hormone is not in uenced by food.8,26 Together 
with ghrelin, this hormone regulates digestive tract 
motoric activity during fasting by increasing the 
gastric emptying rate, small and large intestine motility. 
Motilin binds speci cally with receptors in smooth 
muscle cells in the esophagus, gaster, small and large 
intestine.26 Although the fasting level of motilin in FD 
patients is the same with healthy individuals, when 
motilin is given exogen intravenously, inhibition 
of accomodation re ex in gastric proximal is larger 
compared to healthy individuals.8
ROLE OF DIGESTIVE TRACT HORMONE IN 
FUNCTIONAL DYSPEPSIA
From various digestive tract hormones which 
play role in FD pathophysiology, it seems that only 
motilin and ghrelin are further developed as new 
therapy modality in FD through hormonal approach 
(see Table 1).
Erithromycin, a macrolide class antibiotic, has 
been long known may increase gastric emptying rate 
in diabetic patients because it has strong gastrokinetic 
effect. This is actually caused by erythromycin works 
in motilin receptor.3 We have known that motilin 
is a hormone which increase gastric emptying rate, 
small and large intestine motility. Other drugs, such 
as mitemcinal has been reported to increase gastric 
emptying rate and decrease symptoms of nausea, 
stomach fullness, and stomachache in FD patients. 
This could be understood considering that mimtecinal 
is motilin agonist receptor. However, overstimulation 
to motilin receptor may induce vomiting.11 Currently, 
it is developed a research which give ghrelin receptor 
agonist TZP-01, in diabetic patients with gastroparesis. 
The result was reduced dyspepsia symptoms.8
Table 1. Motilin and ghrelin receptors agonist as therapy in 
gastrointestinal disturbance11
Hormonal 
approach
Component Remarks
Motilin 
receptor 
agonist
Mitemcinal 
(GM-611)
Phase II
Was reported may improve 
symproms in diabetic patients 
with gastroparesis compared to 
placebo, given orally
PF – 045480434
(KOS-2187)
Preclinical
Proven effective as a gastric 
prokinetic agent in study with 
dogs
ABT-229 Cancelled
Failed to overcome symptoms 
in type I DM patients with 
functional dyspepsia
Ghrelin 
receptor 
agonist
TZP-101 Phase II
A pilot study revealed 
improvement of gastroparesis 
symptoms after intravenous 
administration
DM: diabetes mellitus
CONCLUSION
Digestive tract hormones are known to play role 
in FD pathophysiology, thus it is not surprising if 
currently it has been developed new modalities using 
hormonal approach as therapy in gastrointestinal 
disturbance.
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